Application 213382
- Type
- ANDA
- Sponsor
- HYBIO
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | GLATIRAMER ACETATE | GLATIRAMER ACETATE | INJECTABLE;SUBCUTANEOUS | 20MG/ML | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A213382-001 | GLATIRAMER ACETATE | GLATIRAMER ACETATE | 20MG/ML | INJECTABLE / SUBCUTANEOUS | AP | 2026-02-11 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A213382-001 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A213382-001 | GLATIRAMER ACETATE | 20MG/ML | INJECTABLE / SUBCUTANEOUS | AP | 2026-02-11 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A213382-001 | GLATIRAMER ACETATE | 20MG/ML | INJECTABLE / SUBCUTANEOUS | AP | 2026-02-11 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A213382-001 | GLATIRAMER ACETATE | 20MG/ML | INJECTABLE / SUBCUTANEOUS | AP | 2026-02-11 | 011fe1cb6892… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A213382-001 | GLATIRAMER ACETATE | 20MG/ML | INJECTABLE / SUBCUTANEOUS | AP | 2026-02-11 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A213382-001 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A213382-001 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A213382-001 | AP | 1 | 011fe1cb6892… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A213382-001 | AP | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Glatiramer Acetate | GLATIRAMER ACETATE | AJENAT PHARMACEUTICALS LLC | 1ec10223-880d-402f-a759-9cd179bf09de | 2026-09-10 | Boxed warning, Warnings, Adverse reactions | Glatiramer Acetate GLATIRAMER ACETATE |
| GLATIRAMER ACETATE | GLATIRAMER ACETATE | Zydus Pharmaceuticals USA Inc. | 0aa4ff2a-ce8e-46cd-830f-a264cc582be2 | 2026-08-19 | Boxed warning, Warnings, Adverse reactions | GLATIRAMER ACETATE GLATIRAMER ACETATE |
| Glatopa | GLATIRAMER ACETATE | Sandoz Inc | 5f01e40a-b6f6-40fb-b37c-3d06f1428e86 | 2026-07-15 | Boxed warning, Warnings, Adverse reactions | GLATIRAMER ACETATE |
| Copaxone | GLATIRAMER ACETATE | Teva Neuroscience, Inc. | aa88f583-4f5f-433b-80b4-1f4c9fb28357 | 2026-06-23 | Boxed warning, Warnings, Adverse reactions | GLATIRAMER ACETATE |
| Glatiramer Acetate | GLATIRAMER ACETATE INJECTION | UPSHER-SMITH LABORATORIES, LLC | 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 | 2026-01-15 | Boxed warning, Warnings, Adverse reactions | Glatiramer Acetate |
| GLATIRAMER ACETATE | GLATIRAMER ACETATE | Italfarmaco SpA | 1b3a60de-2191-4b15-be69-01329da87711 | 2025-10-31 | GLATIRAMER ACETATE GLATIRAMER ACETATE | |
| Glatopa | GLATIRAMER ACETATE | Bryant Ranch Prepack | 0679689e-8930-4d6a-b922-5125082b2716 | 2025-03-27 | Warnings, Adverse reactions | GLATIRAMER ACETATE |
| Glatopa | GLATIRAMER ACETATE | Bryant Ranch Prepack | 028fdf0e-2340-407b-bcd8-5a99accdddbf | 2025-03-27 | Warnings, Adverse reactions | GLATIRAMER ACETATE |
| Glatiramer Acetate | GLATIRAMER ACETATE | Sun Pharmaceutical Industries, Inc. | f90cc5f5-56a1-48dc-a4fc-0ae89ef61deb | 2025-02-20 | Boxed warning, Warnings, Adverse reactions | Glatiramer Acetate GLATIRAMER ACETATE |
| Glatiramer Acetate | GLATIRAMER ACETATE | Sun Pharmaceutical Industries, Inc. | dfacc3e2-5c91-41de-a377-873276a5cf67 | 2025-02-18 | Boxed warning, Warnings, Adverse reactions | Glatiramer Acetate GLATIRAMER ACETATE |
| Glatiramer Acetate | GLATIRAMER ACETATE | Mylan Pharmaceuticals Inc. | f38b5606-d2d7-44ec-912f-46882aa2fa7b | 2025-02-07 | Boxed warning, Warnings, Adverse reactions | Glatiramer Acetate GLATIRAMER ACETATE |
| Glatiramer Acetate | GLATIRAMER | Mylan Pharmaceuticals Inc. | 456a34c7-8511-4000-99a7-ad8f8de6d35e | 2025-02-07 | Boxed warning, Warnings, Adverse reactions | Glatiramer Acetate |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.